SRR1442571
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.358
- MYOGENESIS+0.281
- KRAS_SIGNALING_DN+0.245
- PANCREAS_BETA_CELLS+0.245
- TNFA_SIGNALING_VIA_NFKB+0.217
- HEDGEHOG_SIGNALING+0.215
- ESTROGEN_RESPONSE_EARLY+0.199
- UV_RESPONSE_UP+0.196
- UV_RESPONSE_DN+0.183
- XENOBIOTIC_METABOLISM+0.142
Top 10 suppressed
- MYC_TARGETS_V1-0.555
- E2F_TARGETS-0.514
- G2M_CHECKPOINT-0.465
- INTERFERON_ALPHA_RESPONSE-0.402
- PROTEIN_SECRETION-0.363
- DNA_REPAIR-0.339
- INTERFERON_GAMMA_RESPONSE-0.323
- IL6_JAK_STAT3_SIGNALING-0.310
- MYC_TARGETS_V2-0.299
- ALLOGRAFT_REJECTION-0.274
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1409305 | GTEX | — | 0.927 |
| 2 | SRR1405485 | GTEX | — | 0.914 |
| 3 | SRR1418837 | GTEX | — | 0.906 |
| 4 | SRR1352975 | GTEX | — | 0.893 |
| 5 | SRR1396595 | GTEX | — | 0.871 |
| 6 | SRR1437555 | GTEX | — | 0.865 |
| 7 | SRR1421351 | GTEX | — | 0.861 |
| 8 | SRR1337864 | GTEX | — | 0.857 |
| 9 | SRR1480365 | GTEX | — | 0.856 |
| 10 | SRR603333 | GTEX | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.358 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.281 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.245 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.245 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.217 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.215 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.199 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.196 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.183 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.142 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.135 | Remibrutinib | — uncovered |
| HYPOXIA | 0.095 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.058 | Inavolisib | — uncovered |
| APOPTOSIS | 0.056 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.053 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.036 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.036 | Inavolisib | — uncovered |
| PEROXISOME | 0.033 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |